Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price traded up 3.7% during trading on Tuesday . The stock traded as high as C$0.28 and last traded at C$0.28. Approximately 81,700 shares traded hands during trading, a decline of 68% from the average session volume of 253,091 shares. The stock had previously closed at C$0.27.
Theralase Technologies Stock Performance
The company has a debt-to-equity ratio of 22.13, a quick ratio of 3.40 and a current ratio of 1.37. The company has a market cap of C$82.79 million, a P/E ratio of -20.00 and a beta of -0.57. The firm has a 50 day moving average price of C$0.25 and a 200-day moving average price of C$0.26.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
